Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
Wang J, Jiang B, Li J, Liu L, Du X, Jiang H, Hu J, Yuan M, Sakatani T, Kadokura T, Takeuchi M, Kosako M, Ma X, Girshova L, Tan J, Bondarenko S, Lee LWL, Khuhapinant A, Martynova E, Hasabou N.
Wang J, et al. Among authors: takeuchi m.
Leukemia. 2024 Sep 5. doi: 10.1038/s41375-024-02382-9. Online ahead of print.
Leukemia. 2024.
PMID: 39237634